Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of SYS6002 in Combination With JMT101 and Enlonstobart Injection in Participants With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Next Previous
Trial Profile

A Phase 2 Study of SYS6002 in Combination With JMT101 and Enlonstobart Injection in Participants With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Becotatug (Primary) ; CRB 701 (Primary) ; Enlonstobart (Primary)
  • Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors CSPC Megalith Biopharmaceutical

Most Recent Events

  • 27 Aug 2025 Number of treatment arms increased from 7 to 8 by the addition of Experimental Group 2 arm. Planned patient enrollment is also increased.
  • 27 Aug 2025 Planned number of patients changed from 250 to 430.
  • 27 Aug 2025 Planned primary completion date changed from 30 Sep 2027 to 30 Dec 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top